Product Information
Registration Status: ActiveTARGET TABLET is approved to be sold in Singapore with effective from 1991-10-21. It is marketed by ZYFAS MEDICAL CO, with the registration number of SIN06647P.
This product contains Atenolol 100mg, and Chlorthalidone 25mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by LISAPHARMA SPA in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect.
Indication
For the management of hypertention and long-term management of patients with angina pectoris
Mechanism of Action
Like metoprolol, atenolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles.
Pharmacokinetics
- Absorption
- Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces.
- Distribution
- Metabolism
- Hepatic (minimal)
- Elimination
Toxicity
LD50=2000-3000 mg/kg(orally in mice). Symptoms of an atenolol overdose include a slow heart beat, shortness of breath, fainting, dizziness, weakness, confusion, nausea, and vomiting.
Active Ingredient/Synonyms
1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol | 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide | 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide | Atenololum | Atenolol |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
A benzenesulfonamide-phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. [PubChem]
Indication
For management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.
Mechanism of Action
Chlorthalidone inhibits sodium ion transport across the renal tubular epithelium in the cortical diluting segment of the ascending limb of the loop of Henle. By increasing the delivery of sodium to the distal renal tubule, Chlorthalidone indirectly increases potassium excretion via the sodium-potassium exchange mechanism.
Pharmacokinetics
- Absorption
- Absorbed relatively rapidly after oral administration.
- Distribution
- Metabolism
- Liver
- Elimination
Toxicity
Symptoms of overdose include nausea, weakness, dizziness and disturbances of electrolyte balance.
Active Ingredient/Synonyms
1-keto-3-(3'-Sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline | 1-oxo-3-(3-Sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline | 2-chloro-5-(1-Hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide | 2-chloro-5-(2,3-dihydro-1-Hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide | 3-(4'-chloro-3'-Sulfamoylphenyl)-3-hydroxyphthalimidine | 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine | Chlorphthalidolone | Chlortalidone | Chlorthalidone | Phthalamodine | Phthalamudine | Chlorthalidone |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.